TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18421079

Group type: EXPERIMENTAL
Intervention: Digital images
Number of subjects: 761

Group type: COMPARATOR
Intervention: Film images
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Optimized images
Number of subjects: 761
Study: 18423103

Group type: EXPERIMENTAL
Intervention: Solifenacin 5/10 mg/day
Number of subjects: 440
Study: 18426260

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Citalopram and Escitalopram
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Postpartum (12 weeks)
Number of subjects: 11
Study: 18426988

Group type: EXPERIMENTAL
Intervention: AMD3100 (240 mug/kg by subcutaneous injection)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AMD3100
Number of subjects: 25
Study: 18436082

Group type: EXPERIMENTAL
Intervention: Calcitriol, 0.5 microg, twice weekly for 12 weeks
Number of subjects: 10
Study: 18436120

Group type: EXPERIMENTAL
Intervention: Performance-improvement program
Number of subjects: 8608

Group type: EXPERIMENTAL
Intervention: Evidence-based medications
Number of subjects: 8608

Group type: EXPERIMENTAL
Intervention: Quality of care measures
Number of subjects: 8608

Group type: EXPERIMENTAL
Intervention: Discharge instructions and smoking cessation counseling
Number of subjects: 8608

Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 8608
Study: 18436554

Group type: EXPERIMENTAL
Intervention: Tigecycline therapy (in combination with other antibiotics in 28 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tigecycline therapy
Number of subjects: 42
Study: 18437127

Group type: EXPERIMENTAL
Intervention: Losartan or Atenolol-based treatments
Number of subjects: 0
Study: 18438111

Group type: EXPERIMENTAL
Intervention: APPEAR procedure for neoplasia or trauma
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: APPEAR procedure for ulcerative colitis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ileostomy closure
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Anorectal physiological testing following perineal dissection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transient sexual dysfunction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ileostomy reversal
Number of subjects: 14
Study: 18438123

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Scanning (EIS)
Number of subjects: 216
Study: 18439279

Group type: EXPERIMENTAL
Intervention: e-learning programme
Number of subjects: 3632
Study: 18441370

Group type: EXPERIMENTAL
Intervention: Subretinal delivery of AAV2.hRPE65v2
Number of subjects: 3
Study: 18441371

Group type: EXPERIMENTAL
Intervention: Subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 cDNA
Number of subjects: 3
Study: 18443195

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 18443260

Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (e.g., pneumonia, ischemia, worsening renal function)
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (e.g., ischemia, worsening renal function)
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension as a precipitating factor
Number of subjects: 48612
Study: 18445662

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Surgery (transsphenoidal approach)
Number of subjects: 89
Study: 18447916

Group type: EXPERIMENTAL
Intervention: Online tutorial, interactive skills building workshop, decision support protocol, performance feedback, and educational outreach.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 18447935

Group type: EXPERIMENTAL
Intervention: Good adherence to antipsychotic medication (defined as less than one month without medication)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-adherence to antipsychotic medication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Use of depot-antipsychotics
Number of subjects: 50
Study: 18450881

Group type: EXPERIMENTAL
Intervention: Newborn skin and umbilical cord cleansing
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Maternal fever and prematurity
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Facility delivery, maternal fever, maternal swelling, multiple births
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Low paternal education, Madeshi ethnicity, primiparity
Number of subjects: 23662

Group type: EXPERIMENTAL
Intervention: Maternal infections, prematurity, multiple births
Number of subjects: 23662
Study: 18451319

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) trial at 5 cm H2O
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) trial at 15 cm H2O
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tidal volume of 12 ml/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plateau pressure and tidal volume
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stress to strain ratio (specific lung elastance)
Number of subjects: 80
Study: 18452610

Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg monthly)
Number of subjects: 12
Study: 18456875

Group type: EXPERIMENTAL
Intervention: CD4 T-cell counts remained less than 300/mm(3) throughout the study period
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CD4 T-cell counts normalized after an average of 31 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Developed an opportunistic infection in follow-up
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Developed AIDS-defining clinical conditions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Developed autoimmune diseases
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Died from ICL-related opportunistic infections
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Increased activation and turnover in CD4 T lymphocytes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CD8 T lymphocytopenia (< 180/mm(3)) and degree of CD4 T cell activation (HLA-DR expression) at presentation
Number of subjects: 39
Study: 18457470

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study: 18457580

Group type: EXPERIMENTAL
Intervention: VR group - taught to relax using a VR relaxing environment and audio-visual mobile narratives
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-VR group - taught to relax using the same relaxing narratives without VR support
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waiting list (WL) group - no relaxation training
Number of subjects: 75
Study: 18457586

Group type: EXPERIMENTAL
Intervention: Sepsis-associated delirium group (12 patients)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients without sepsis-associated delirium (4 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with elevated CRP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with elevated S-100beta
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with elevated cortisol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with disturbed autoregulation
Number of subjects: 23
Study: 18458170

Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters of dyssynchrony
Number of subjects: 498
Study: 18463354

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2) intravenous infusion weekly for 4 weeks)
Number of subjects: 60
Study: 18463735

Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin therapy
Number of subjects: 20
Study: 18465380

Group type: EXPERIMENTAL
Intervention: ADHD-C
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ADHD-I
Number of subjects: 121

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 121
Study: 18471323

Group type: EXPERIMENTAL
Intervention: Isoflavone therapy (soy milk containing 47 mg of isoflavonoid per 8 oz serving three times per day for 12 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflavone therapy
Number of subjects: 20
Study: 18473686

Group type: COMPARATOR
Intervention: AAV2 CU h-CLN2 vector administered at a total average dose of 2.5 x 10^12 particle units to 12 locations in the CNS.
Number of subjects: 10

Group type: COMPARATOR
Intervention: AAV2 CU h-CLN2 vector
Number of subjects: 10
Study: 18474099

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia
Number of subjects: 44
Study: 18477573

Group type: EXPERIMENTAL
Intervention: Embryos derived from oocytes with cytoplasmic abnormalities (vacuolar cytoplasm or central granulation)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Grade 2 embryos derived from oocytes with irregular shape or large perivitelline space
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Embryos derived from oocytes with extracytoplasmic abnormalities
Number of subjects: 964
Study: 18477658

Group type: EXPERIMENTAL
Intervention: U-Na measurement in patients not on diuretics
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: FE-UA measurement in patients on diuretics
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of U-Na and FE-UA
Number of subjects: 86
Study: 18477770

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 11

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 11
Study: 18477813

Group type: EXPERIMENTAL
Intervention: BGAThome (web-based Blood Glucose Awareness Training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 18480204

Group type: EXPERIMENTAL
Intervention: Positive cardiac troponin test (defined as cardiac troponin I level of 1.0 microg per liter or higher or cardiac troponin T level of 0.1 microg per liter or higher)
Number of subjects: 67824

Group type: COMPARATOR
Intervention: Negative cardiac troponin test
Number of subjects: 67824
Study: 18482659

Group type: EXPERIMENTAL
Intervention: CYP2C19 *2 carriers
Number of subjects: 797

Group type: COMPARATOR
Intervention: CYP2C19 wild-type homozygotes
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Residual platelet aggregation >14% at pre-discharge
Number of subjects: 797
Study: 18485781

Group type: EXPERIMENTAL
Intervention: Premarin estrogen replacement therapy (ERT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy, age-matched)
Number of subjects: 20
Study: 18487210

Group type: EXPERIMENTAL
Intervention: Current/recent smokers
Number of subjects: 7743

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 7743

Group type: EXPERIMENTAL
Intervention: Current/recent smokers (post-discharge)
Number of subjects: 7743

Group type: COMPARATOR
Intervention: Non-smokers (post-discharge)
Number of subjects: 7743
Study: 18495536

Group type: EXPERIMENTAL
Intervention: Intratumoral JX-594 (10^8 pfu, 3x10^8 pfu, 10^9 pfu, or 3x10^9 pfu) every 3 weeks
Number of subjects: 14
Study: 18504251

Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bortezomib and gemcitabine combination
Number of subjects: 18
Study: 18504323

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Adjusted means for Cornell product
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Adjusted means for Sokolow-Lyon voltage
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Regression of Cornell product left ventricular hypertrophy
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Regression of left ventricular hypertrophy by Sokolow-Lyon criteria
Number of subjects: 9193
Study: 18504334

Group type: EXPERIMENTAL
Intervention: RAPID (resuscitation with actual performance integrated debriefing)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (historical cohort with feedback but without RAPID)
Number of subjects: 123
Study: 18504339

Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 9105

Group type: COMPARATOR
Intervention: No gout
Number of subjects: 9105
Study: 18507490

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18507817

Group type: EXPERIMENTAL
Intervention: Fast-track palliative care service (immediate referral)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard best practice (12-week wait)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 18507843

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 81
Study: 18507871

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of influenza vaccine (129 patients)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Subcutaneous administration of influenza vaccine (100 patients)
Number of subjects: 229
Study: 18509084

Group type: EXPERIMENTAL
Intervention: Autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin-2 (IL-2) injections
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T cells produced by limiting dilution methods
Number of subjects: 7
Study: 18509175

Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation (COS) with letrozole and gonadotropins
Number of subjects: 215

Group type: COMPARATOR
Intervention: No fertility-preserving procedure (Control)
Number of subjects: 215
Study: 18510963

Group type: EXPERIMENTAL
Intervention: Short-lasting atrial fibrillation (AF) induced and maintained for 15 min
Number of subjects: 35
Study: 18511703

Group type: EXPERIMENTAL
Intervention: ICU-acquired paresis (ICUAP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (no ICUAP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ICUAP
Number of subjects: 5
Study: 18514203

Group type: EXPERIMENTAL
Intervention: Baseline plasma IL-18 levels (274.1 pg/mL) in women who developed CVD
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: IL-18 levels at or above the 90th percentile (442 pg/mL)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: IL-18 levels above the 90th percentile
Number of subjects: 506

Group type: COMPARATOR
Intervention: Baseline plasma IL-18 levels (233.8 pg/mL) in healthy controls
Number of subjects: 506
Study: 18515576

Group type: EXPERIMENTAL
Intervention: Epiretinal prostheses with 16 platinum stimulating electrodes (260- or 520-microm diameter)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epiretinal prostheses
Number of subjects: 6
Study: 18515577

Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with a 3.4-mm-diameter circle centered on the optic nerve head (ONH)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with shifted 3.4-mm circles (horizontal, vertical, diagonal)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with a 3.4-mm-diameter circle
Number of subjects: 17
Study: 18519811

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (immunotoxin targeting CD25(high) Treg cells)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dendritic cells modified with the fowlpox vector rF-CEA(6D)-TRICOM (following Treg-cell depletion)
Number of subjects: 15
Study: 18520226

Group type: EXPERIMENTAL
Intervention: Robotic-assisted cholecystectomy (Da Vinci Robot, Intuitive Surgical)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 100
Study: 18520231

Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization using glass microspheres
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization using resin microspheres
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization (both glass and resin)
Number of subjects: 42
Study: 18522979

Group type: EXPERIMENTAL
Intervention: Graded estrogen infusion
Number of subjects: 11
Study: 18523152

Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 antibody
Number of subjects: 0
Study: 18534024

Group type: EXPERIMENTAL
Intervention: Cervical myofascial OMT
Number of subjects: 17

Group type: COMPARATOR
Intervention: Touch-only sham OMT
Number of subjects: 17

Group type: COMPARATOR
Intervention: No-touch control
Number of subjects: 17
Study: 18535255

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (surgical treatment)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Medical therapy (medical treatment)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: mBODE change
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: mBODE increase of more than 1 point
Number of subjects: 1218
Study: 18540943

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 500 microg every 3 weeks (Q3W)
Number of subjects: 206
Study: 18541822

Group type: EXPERIMENTAL
Intervention: African American patients with ADHF
Number of subjects: 29862

Group type: EXPERIMENTAL
Intervention: African American patients in the nonischemic subgroup
Number of subjects: 29862

Group type: EXPERIMENTAL
Intervention: African American patients in the ischemic subgroup
Number of subjects: 29862
Study: 18541828

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL)
Number of subjects: 5801

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 5801

Group type: EXPERIMENTAL
Intervention: Total to high-density lipoprotein cholesterol ratio
Number of subjects: 5801

Group type: EXPERIMENTAL
Intervention: Multivariate analyses of lipoprotein parameters
Number of subjects: 5801
Study: 18544707

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Risk genotype at HHEX rs1111875
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: LOC387761 risk genotype
Number of subjects: 3548

Group type: COMPARATOR
Intervention: None of the selected SNPs
Number of subjects: 3548
Study: 18545693

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (3 g, 6 g, 12 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (12 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 30
Study: 18547438

Group type: EXPERIMENTAL
Intervention: Standard CPR plus AECD monitoring (PowerHeart CRM)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard CPR (code team)
Number of subjects: 192
Study: 18549175

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 286
Study: 18549890

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 113
Study: 18551042

Group type: EXPERIMENTAL
Intervention: CBR3 11G>A variant
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CBR3 730G>A variant
Number of subjects: 101
Study: 18553028

Group type: EXPERIMENTAL
Intervention: BMMC transplantation (9.6 +/- 2.6 x 10^7 cells) at 20 sites in the ventricular wall via thoracotomy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BMMC transplantation
Number of subjects: 9
Study: 18554762

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 600 mg/m(2)/dose, twice daily for 24 months.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment for 18.6 +/- 8.0 months, with a final dosage of 381 +/- 241 mg/m(2) twice daily.
Number of subjects: 12
Study: 18559166

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (10.5 mg daily for an average of 167 days)
Number of subjects: 215
Study: 18559695

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 6 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: HMGCR full-length transcript
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: HMGCR enzyme activity in cells enriched in HMGCRv_1
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Common HMGCR single-nucleotide polymorphism (rs3846662)
Number of subjects: 170
Study: 18559696

Group type: EXPERIMENTAL
Intervention: Aliskiren (600 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Captopril (25 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aliskiren (on high-sodium diet)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aliskiren (both diets)
Number of subjects: 26
Study: 18560516

Group type: EXPERIMENTAL
Intervention: Cultured islet cell grafts under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF) maintenance immunosuppression
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Presence of cellular autoimmunity before transplantation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Presence of cellular autoimmunity after transplantation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients without pre-existent T-cell autoreactivity
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients reactive to both islet autoantigens GAD and IA-2 before transplantation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Autoantibody levels and cellular alloreactivity
Number of subjects: 21
Study: 18561930

Group type: EXPERIMENTAL
Intervention: Circumferential ablation with focal ablation
Number of subjects: 70
Study: 18564200

Group type: EXPERIMENTAL
Intervention: AHA-defined metabolic syndrome
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: IDF-defined metabolic syndrome
Number of subjects: 320
Study: 18565399

Group type: EXPERIMENTAL
Intervention: Presence of late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR)
Number of subjects: 65
Study: 18565793

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 106
Study: 18565861

Group type: EXPERIMENTAL
Intervention: Severe ECG abnormality
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of atrial tachyarrhythmia
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 406